$ANIK
Anika Therapeutics, Inc.

2021 Q4 Form 10-Q Financial Statement

#000117184321007580 Filed on November 05, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $35.82M $39.54M $31.69M
YoY Change 9.58% 24.74% 6.72%
Cost Of Revenue $17.69M $16.51M $14.35M
YoY Change 10.96% 15.07% 141.15%
Gross Profit $18.13M $23.02M $17.34M
YoY Change 8.3% 32.75% -26.96%
Gross Profit Margin 50.62% 58.23% 54.72%
Selling, General & Admin $20.43M $17.50M $15.90M
YoY Change 34.6% 10.04% 110.94%
% of Gross Profit 112.67% 76.01% 91.7%
Research & Development $6.000M $7.673M $5.217M
YoY Change -21.36% 47.08% 25.47%
% of Gross Profit 33.09% 33.33% 30.08%
Depreciation & Amortization $3.730M $3.576M $3.500M
YoY Change 6.57% 2.17% 130.26%
% of Gross Profit 20.57% 15.53% 20.18%
Operating Expenses $27.26M $25.17M $21.12M
YoY Change 19.5% 19.19% 80.56%
Operating Profit -$9.123M $1.300M -$7.927M
YoY Change 50.42% -116.4% -165.79%
Interest Expense -$47.00K -$48.00K -$228.0K
YoY Change -100.38% -78.95% -147.3%
% of Operating Profit -3.69%
Other Income/Expense, Net
YoY Change
Pretax Income -$9.170M $1.252M -$8.155M
YoY Change -49.45% -115.35% -165.08%
Income Tax -$3.377M $700.0K -$1.700M
% Of Pretax Income 55.91%
Net Earnings -$5.793M $558.0K -$6.411M
YoY Change -63.0% -108.7% -169.68%
Net Earnings / Revenue -16.17% 1.41% -20.23%
Basic Earnings Per Share $0.04 -$0.45
Diluted Earnings Per Share -$401.3K $0.04 -$0.45
COMMON SHARES
Basic Shares Outstanding 14.44M 14.43M 14.21M
Diluted Shares Outstanding 14.65M 14.21M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $94.39M $90.98M $124.8M
YoY Change -3.98% -27.1% -27.94%
Cash & Equivalents $94.39M $90.98M $104.2M
Short-Term Investments $0.00 $20.50M
Other Short-Term Assets $8.289M $7.433M $6.200M
YoY Change -5.81% 19.89% 313.33%
Inventory $36.01M $35.02M $47.88M
Prepaid Expenses
Receivables $29.84M $32.35M $23.01M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $168.5M $165.8M $201.9M
YoY Change -4.99% -17.88% -9.8%
LONG-TERM ASSETS
Property, Plant & Equipment $47.60M $49.11M $51.63M
YoY Change -5.95% -4.88% -0.23%
Goodwill $7.781M $7.950M $32.42M
YoY Change -7.51% -75.48% 332.89%
Intangibles $82.38M $85.02M $94.29M
YoY Change -9.63% -9.83% 1127.75%
Long-Term Investments
YoY Change
Other Assets $20.29M $23.67M $13.23M
YoY Change 31.55% 78.97% 129.58%
Total Long-Term Assets $179.0M $187.2M $214.5M
YoY Change -4.9% -12.74% 123.95%
TOTAL ASSETS
Total Short-Term Assets $168.5M $165.8M $201.9M
Total Long-Term Assets $179.0M $187.2M $214.5M
Total Assets $347.5M $352.9M $416.3M
YoY Change -4.94% -15.23% 30.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.633M $7.942M $6.800M
YoY Change -15.04% 16.79% 151.67%
Accrued Expenses $17.66M $17.34M $24.20M
YoY Change 20.95% -28.35% 184.71%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $188.0K $200.0K
YoY Change 88.0%
Total Short-Term Liabilities $29.80M $28.77M $31.14M
YoY Change -19.18% -7.6% 178.15%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $25.00M
YoY Change -100.0%
Other Long-Term Liabilities $1.258M $1.489M $987.0K
YoY Change 1.13% 50.86% 165.32%
Total Long-Term Liabilities $1.258M $1.489M $25.99M
YoY Change 1.13% -94.27% 6885.75%
TOTAL LIABILITIES
Total Short-Term Liabilities $29.80M $28.77M $31.14M
Total Long-Term Liabilities $1.258M $1.489M $25.99M
Total Liabilities $31.05M $30.26M $57.13M
YoY Change -18.52% -47.03% 393.87%
SHAREHOLDERS EQUITY
Retained Earnings $225.6M $231.4M $237.1M
YoY Change 1.87% -2.42% -1.77%
Common Stock $67.23M $64.01M $52.65M
YoY Change 21.13% 21.58% 12.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $287.1M $290.1M $284.5M
YoY Change
Total Liabilities & Shareholders Equity $347.5M $352.9M $416.3M
YoY Change -4.94% -15.23% 30.28%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$5.793M $558.0K -$6.411M
YoY Change -63.0% -108.7% -169.68%
Depreciation, Depletion And Amortization $3.730M $3.576M $3.500M
YoY Change 6.57% 2.17% 130.26%
Cash From Operating Activities $4.472M $2.062M $5.870M
YoY Change 72.66% -64.87% -41.59%
INVESTING ACTIVITIES
Capital Expenditures -$1.127M -$1.284M -$270.0K
YoY Change 150.44% 375.56% -37.21%
Acquisitions
YoY Change
Other Investing Activities -$113.0K -$11.00K $7.000M
YoY Change -100.66% -100.16% 176.68%
Cash From Investing Activities -$1.240M -$1.295M $6.730M
YoY Change -107.38% -119.24% 220.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 60.00K -6.982M -25.18M
YoY Change -100.21% -72.27% -216.04%
NET CHANGE
Cash From Operating Activities 4.472M 2.062M 5.870M
Cash From Investing Activities -1.240M -1.295M 6.730M
Cash From Financing Activities 60.00K -6.982M -25.18M
Net Change In Cash 3.292M -6.215M -12.58M
YoY Change -137.8% -50.6% -137.16%
FREE CASH FLOW
Cash From Operating Activities $4.472M $2.062M $5.870M
Capital Expenditures -$1.127M -$1.284M -$270.0K
Free Cash Flow $5.599M $3.346M $6.140M
YoY Change 84.18% -45.5% -41.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
14436773
CY2021Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1358000 USD
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1523000 USD
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1250000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1250000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
18144000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
47164000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
45487000 USD
CY2021Q3 us-gaap Gross Profit
GrossProfit
23023000 USD
CY2020Q3 us-gaap Gross Profit
GrossProfit
17343000 USD
us-gaap Gross Profit
GrossProfit
64809000 USD
us-gaap Gross Profit
GrossProfit
52282000 USD
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7673000 USD
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
63864000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
55355000 USD
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5319000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4542000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
231371000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14351000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
221444000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
290060000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
272400000 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
352930000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
365605000 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
39536000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31694000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
111973000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
97769000 USD
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
16513000 USD
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14436000
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14436000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14329000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14329000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0 USD
CY2021Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
0 USD
CY2020Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
0 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
90976000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95817000 USD
CY2021Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
USD
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
2501000 USD
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
32352000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
24102000 USD
CY2021Q3 us-gaap Inventory Net
InventoryNet
35019000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
46209000 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7433000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8754000 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
165780000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
177383000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
49111000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50613000 USD
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21397000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22619000 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
23671000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15420000 USD
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
85021000 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
91157000 USD
CY2021Q3 us-gaap Goodwill
Goodwill
7950000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
8413000 USD
CY2021Q3 us-gaap Assets
Assets
352930000 USD
CY2020Q4 us-gaap Assets
Assets
365605000 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
7942000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8984000 USD
CY2021Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
17339000 USD
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
14793000 USD
CY2021Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
3490000 USD
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
13090000 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
28771000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
36867000 USD
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1489000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1244000 USD
CY2021Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
0 USD
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
22320000 USD
CY2021Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
12972000 USD
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
11895000 USD
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19638000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20879000 USD
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
144000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
143000 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5217000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21327000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15799000 USD
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
17500000 USD
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
15903000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
53664000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
44884000 USD
CY2021Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
anik Amortization Of Acquisition Related Inventory Step Up
AmortizationOfAcquisitionRelatedInventoryStepUp
7396000 USD
anik Operating Lease Rightofuse Asset Amortization
OperatingLeaseRightofuseAssetAmortization
1312000 USD
anik Operating Lease Rightofuse Asset Amortization
OperatingLeaseRightofuseAssetAmortization
1136000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
558000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-6411000 USD
us-gaap Net Income Loss
NetIncomeLoss
9927000 USD
us-gaap Net Income Loss
NetIncomeLoss
-8326000 USD
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-467000 USD
CY2020Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
522000 USD
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1252000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8155000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
11597000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10487000 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
694000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1744000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1670000 USD
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14202000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2161000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
558000 USD
CY2020Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
18144000 USD
CY2021Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-3450000 USD
CY2020Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
4150000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-21920000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-16176000 USD
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
21723000 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
25270000 USD
us-gaap Costs And Expenses
CostsAndExpenses
53071000 USD
us-gaap Costs And Expenses
CostsAndExpenses
62651000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
1300000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7927000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
11738000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-10369000 USD
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-48000 USD
CY2020Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-228000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-141000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-118000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-6411000 USD
us-gaap Net Income Loss
NetIncomeLoss
9927000 USD
us-gaap Net Income Loss
NetIncomeLoss
-8326000 USD
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.04
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.69
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.04
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.68
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14429000
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14205000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14389000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14202000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14647000
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14205000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14588000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-21920000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-16176000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7724000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
272400000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1000 USD
CY2021Q1 anik Apic Sharebased Payment Arrangement Increase Decrease For Cost Recognition Benefit
APICSharebasedPaymentArrangementIncreaseDecreaseForCostRecognitionBenefit
2259000 USD
CY2021Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
333000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
2838000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-509000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
276656000 USD
CY2020Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
-0 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
5793000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-129000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
293694000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
68000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-777000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
602000 USD
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
91000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5889000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
9150000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
640000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2021Q2 anik Apic Sharebased Payment Arrangement Increase Decrease For Cost Recognition Benefit
APICSharebasedPaymentArrangementIncreaseDecreaseForCostRecognitionBenefit
2797000 USD
CY2021Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
19000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
6531000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
199000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
286804000 USD
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
373000 USD
CY2021Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2021Q3 anik Apic Sharebased Payment Arrangement Increase Decrease For Cost Recognition Benefit
APICSharebasedPaymentArrangementIncreaseDecreaseForCostRecognitionBenefit
2863000 USD
CY2021Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
71000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
558000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-467000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
290060000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
288378000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
-0 USD
CY2020Q1 anik Apic Sharebased Payment Arrangement Increase Decrease For Cost Recognition Benefit
APICSharebasedPaymentArrangementIncreaseDecreaseForCostRecognitionBenefit
-207000 USD
CY2020Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
141000 USD
CY2020Q2 anik Apic Sharebased Payment Arrangement Increase Decrease For Cost Recognition Benefit
APICSharebasedPaymentArrangementIncreaseDecreaseForCostRecognitionBenefit
2240000 USD
CY2020Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
59000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-7708000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
209000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
288444000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2020Q3 anik Apic Sharebased Payment Arrangement Increase Decrease For Cost Recognition Benefit
APICSharebasedPaymentArrangementIncreaseDecreaseForCostRecognitionBenefit
1920000 USD
CY2020Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
24000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-6411000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
522000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
284451000 USD
us-gaap Net Income Loss
NetIncomeLoss
9927000 USD
us-gaap Net Income Loss
NetIncomeLoss
-8326000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4702000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4545000 USD
anik Amortization Of Acquisition Related Intangible Assets
AmortizationOfAcquisitionRelatedIntangibleAssets
5885000 USD
anik Amortization Of Acquisition Related Intangible Assets
AmortizationOfAcquisitionRelatedIntangibleAssets
5418000 USD
anik Amortization Of Acquisition Related Inventory Step Up
AmortizationOfAcquisitionRelatedInventoryStepUp
6244000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-831000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-287000 USD
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
1025000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
7919000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
3953000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
1018000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-3302000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-60000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-482000 USD
us-gaap Inventory Write Down
InventoryWriteDown
3702000 USD
us-gaap Inventory Write Down
InventoryWriteDown
4205000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
13000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
19000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8321000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-7811000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
7117000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
8840000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1864000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
989000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-702000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1904000 USD
anik Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-1247000 USD
anik Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-1286000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3104000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2340000 USD
anik Increase Decrease In Contingent Consideration
IncreaseDecreaseInContingentConsideration
-2780000 USD
anik Increase Decrease In Contingent Consideration
IncreaseDecreaseInContingentConsideration
0 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-423000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
222000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3925000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
10478000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
363000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
93859000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2501000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
27000000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
-0 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
20035000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4016000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1179000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1878000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-88073000 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
210000 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
155000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
-0 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
25351000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
50000000 USD
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
7220000 USD
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
-0 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
423000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
224000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1014000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
68000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-6839000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24338000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-49000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4841000 USD
CY2021Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
16084000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
90976000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
104216000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
195000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
44000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
220000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
anik Consideration For Acquisitions Included In Accounts Payable And Accrued Expenses
ConsiderationForAcquisitionsIncludedInAccountsPayableAndAccruedExpenses
0 USD
anik Consideration For Acquisitions Included In Accounts Payable And Accrued Expenses
ConsiderationForAcquisitionsIncludedInAccountsPayableAndAccruedExpenses
1209000 USD
anik Acquisition Related Contingent Consideration
AcquisitionRelatedContingentConsideration
0 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-53247000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
95817000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
157463000 USD
anik Acquisition Related Contingent Consideration
AcquisitionRelatedContingentConsideration
69076000 USD
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
220000 USD
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
0 USD
us-gaap Nature Of Operations
NatureOfOperations
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: top; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><em style="font: inherit;">1.</em></b></p> </td><td style="vertical-align: top; width: 92%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Nature of Business</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Anika Therapeutics, Inc. <span style="text-decoration: underline; ">(</span>the “Company”) is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, including in the areas of osteoarthritis (“OA”) pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In early <em style="font: inherit;">2020,</em> the Company expanded its overall technology platform through its strategic acquisitions of Parcus Medical, LLC (“Parcus Medical”), a sports medicine implant and instrumentation solutions provider focused on sports medicine and soft tissue repair, and Arthrosurface, Inc. (“Arthrosurface”), a company specializing in less invasive, bone preserving partial and total joint replacement solutions. These acquisitions broadened the Company’s product portfolio, developed over its nearly <em style="font: inherit;">30</em> years of expertise in hyaluronic acid technology, into joint preservation and restoration, added high-growth revenue streams, increased its commercial capabilities, diversified its revenue base, and expanded its product pipeline and research and development expertise.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company is subject to risks common to companies in the life sciences industry including, but <em style="font: inherit;">not</em> limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with U.S. Food and Drug Administration (“FDA”) and foreign regulations and approval requirements, as well as the ability to grow the Company’s business through appropriate commercial strategies.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">There continue to be uncertainties regarding the pandemic of the novel coronavirus (“COVID-<em style="font: inherit;">19”</em>), and the Company is closely monitoring the impact of COVID-<em style="font: inherit;">19</em> on all aspects of its business, including how it will impact its customers, employees, suppliers, vendors, and business partners. The Company is unable to predict the specific impact that COVID-<em style="font: inherit;">19</em> <em style="font: inherit;"> may </em>have on its financial position and operations moving forward due to the numerous uncertainties. Any estimates made herein <em style="font: inherit;"> may </em>change as new events occur and additional information is obtained, and actual results could differ materially from any estimates made herein under different assumptions or conditions. The Company will continue to assess the evolving impact of COVID-<em style="font: inherit;">19.</em></p>
CY2020Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
14801000 USD
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
101722000 USD
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-7328000 USD
CY2021Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-3500000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-21900000 USD
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
14852000 USD
CY2021Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
12795000 USD
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
12811000 USD
CY2021Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
28935000 USD
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
33347000 USD
CY2021Q3 anik Inventory Raw Materials Work In Process And Finished Goods Net Of Reserve Total
InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal
57814000 USD
CY2020Q4 anik Inventory Raw Materials Work In Process And Finished Goods Net Of Reserve Total
InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal
61010000 USD
CY2021Q3 us-gaap Inventory Net
InventoryNet
35019000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
46209000 USD
CY2021Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
22795000 USD
CY2021Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
112736000 USD
CY2021Q3 anik Accumulated Currency Translation Adjustment
AccumulatedCurrencyTranslationAdjustment
3131000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
24584000 USD
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
85021000 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
91157000 USD
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P13Y
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2000000.0 USD
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1900000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5900000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5400000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
8413000 USD
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-463000 USD
CY2021Q3 us-gaap Goodwill
Goodwill
7950000 USD
CY2021Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
900000 USD
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
200000 USD
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8794000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7345000 USD
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2046000 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3438000 USD
CY2021Q3 anik Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
2463000 USD
CY2020Q4 anik Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
1429000 USD
CY2021Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
2494000 USD
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1144000 USD
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
17339000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
14793000 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
39536000 USD
CY2021Q3 anik Percentage Of Net Revenue
PercentageOfNetRevenue
1 pure
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31694000 USD
CY2020Q3 anik Percentage Of Net Revenue
PercentageOfNetRevenue
1 pure
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
111973000 USD
anik Percentage Of Net Revenue
PercentageOfNetRevenue
1 pure
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
97769000 USD
anik Percentage Of Net Revenue
PercentageOfNetRevenue
1 pure
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1900000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1184992
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
39.65
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4654000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
304172
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
44.01
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y3M18D
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2863000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1920000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7919000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3954000 USD
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
896819
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
41.50
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
493628
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
37.67
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
27851
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
34.62
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
234000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
177604
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
44.32
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
812000 USD
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1184992
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
39.65
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y6M
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
4654000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
493628
CY2020Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
199000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14647000
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14205000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14588000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14202000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
700000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1700000 USD
CY2021Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.554 pure
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.144 pure
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1700000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2200000 USD
CY2020Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.214 pure
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.206 pure
anik Effective Income Tax Rate Reconciliationchange In Fair Value Of Business Acquisition Contingent Consideration Liabilities Amount
EffectiveIncomeTaxRateReconciliationchangeInFairValueOfBusinessAcquisitionContingentConsiderationLiabilitiesAmount
1100000 USD
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14429000
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14205000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14389000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14202000
CY2021Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
218000

Files In Submission

Name View Source Status
0001171843-21-007580-index-headers.html Edgar Link pending
0001171843-21-007580-index.html Edgar Link pending
0001171843-21-007580.txt Edgar Link pending
0001171843-21-007580-xbrl.zip Edgar Link pending
anik-20210930.xsd Edgar Link pending
anik-20210930_cal.xml Edgar Link unprocessable
anik-20210930_def.xml Edgar Link unprocessable
anik-20210930_lab.xml Edgar Link unprocessable
anik-20210930_pre.xml Edgar Link unprocessable
anik20210930_10q.htm Edgar Link pending
anik20210930_10q_htm.xml Edgar Link completed
ex_295887.htm Edgar Link pending
ex_295888.htm Edgar Link pending
ex_295889.htm Edgar Link pending
ex_302187.htm Edgar Link pending
ex_302188.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending